Bortezomib For Injection IP

Bortezomib For Injection IP Specification

Indication
Multiple Myeloma and Mantle Cell Lymphoma

Salt Composition
Bortezomib

Origin
India

Dosage Form
Tablet

Enzyme Types
Other

Feature
Sterile, Single-Use Vial

Application
For Intravenous or Subcutaneous Use

Physical Color/Texture
White to Off-White Lyophilized Powder

Fermentation Smell
Odorless

Enzymatic Activity
Inhibits 26S Proteasome Activity

Storage Instructions
Cool & Dry Place

Shelf Life
24 months

Strength
2 mg/vial

Prescription Status
Prescription Only Medication

Route of Administration
Intravenous (IV) or Subcutaneous (SC)

Contraindications
Hypersensitivity to Bortezomib or Boron

Packaging Type
Vial with Flip-Off Seal

Reconstitution Solution
0.9% Sodium Chloride Injection

Product Code
Refer to packaging for exact code

Administration
Prepared as Solution and Administered via IV or SC

Bortezomib For Injection IP Trade Information

Minimum Order Quantity
5000 Pieces

Supply Ability
100 Pieces Per Day

Delivery Time
3-4 Days

Main Export Market(s)
Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa

Main Domestic Market
All India

About Bortezomib For Injection IP

By keeping track with the current market growth, we are offering Bortezomib For Injection IP. This medication is used to treat people with multiple myeloma. Moreover, Bortezomib For Injection IP comes in a class of medications called antineoplastic agents. Apart from this, the offered medication is tested on different measures before delivering at customers end.

Effective Treatment for Serious Hematological Cancers

Bortezomib For Injection IP is a crucial therapeutic option for patients with Multiple Myeloma and Mantle Cell Lymphoma. By inhibiting 26S proteasome activity, it helps in reducing cancer cell proliferation, thus enhancing treatment outcomes. Prepared as a sterile solution, it offers flexibility in administration through intravenous or subcutaneous routes, ensuring adaptability to patient needs.

Sterile, Convenient, and Reliable Formulation

Each vial is produced under stringent quality standards, ensuring sterility and consistency. Its easy-to-reconstitute lyophilized form and flip-off seal design facilitate quick and safe preparation. Physicians and pharmacists benefit from clear packaging and instructions, promoting accurate dosing and minimizing the risk of contamination during handling.

FAQ's of Bortezomib For Injection IP:

Q: How should Bortezomib For Injection IP be prepared for administration?

A: Reconstitute the lyophilized product using 0.9% Sodium Chloride Injection as per the instructions provided. Once dissolved, the solution is ready for administration either intravenously or subcutaneously by a healthcare professional.

Q: What are the main indications for using this medication?

A: Bortezomib For Injection IP is primarily used in the treatment of Multiple Myeloma and Mantle Cell Lymphoma. It works by inhibiting 26S proteasome activity, reducing the growth of malignant cells.

Q: When is Bortezomib contraindicated?

A: This medication should not be used in patients who have a known hypersensitivity to Bortezomib, boron, or any of the excipients in the formulation. Consult your physician before use if you have a history of allergic reactions to similar agents.

Q: Where should Bortezomib For Injection IP be stored?

A: Store the vials in a cool, dry place as per the storage instructions. Avoid exposure to direct light or excessive heat to preserve the efficacy and stability of the medication.

Q: What is the process for administering Bortezomib For Injection IP?

A: After reconstitution, the solution should be administered by a qualified healthcare provider either through intravenous (IV) infusion or subcutaneous (SC) injection, depending on the patient's needs and doctor's recommendation.

Q: How does this medication benefit patients with cancer?

A: By inhibiting the 26S proteasome, Bortezomib interferes with pathways critical for cancer cell survival, helping to control disease progression and improve quality of life for patients with Multiple Myeloma and Mantle Cell Lymphoma.